Henrik Zetterberg

Gehirnveränderungen bei Alzheimer beginnen Jahrzehnte vor schwerem Gedächtnisverlust

GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy.

Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data.

Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein disease.

Aging-related matrix metallopeptidase 10 and osteopontin levels are associated with pathology, cognitive decline, and age at onset in Alzheimer's disease.

Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?

Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer's disease.

Association of acute blood biomarkers with diffusion tensor imaging and outcome in patients with traumatic brain injury presenting with GCS of 13-15.

Die Bewertungsmethode für Gedächtnistests zeigt eine stärkere Verbindung zu Blutmarkern von Alzheimer

Association between FDG- and TSPO-PET signals across human and animal studies investigating neurodegenerative conditions: a systematic review.

Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid.

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer's disease.

Associations of lifestyle factors with amyloid pathology in persons without dementia.

Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles.

Prognostic Value of A/T/N Biomarkers: Comparing Plasma and Imaging Modalities in Alzheimer Disease.

Plasma p-tau217 correlates strongly with cerebrospinal fluid Aβ42 and increases over a ten-year period in amyloid-positive, non-demented very old men.

Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration.

Development of language composites for enhanced sensitivity to multiple plasma biomarkers.